Eurofins Scientific (ERF.PA): analysis and signal as of September 2, 2026
In short
The signal remains weak on Eurofins Scientific, with a vote of 3/3 and a score of 3,5. The main reason lies in earnings growth underpinned by the margin, the share repurchase and finance costs, despite revenue rising by only 2,5 %, against a background of distrust inherited from the Muddy Waters case.
- Current signal
- weak (vote 3/3)
- Deterministic score
- +3.5 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : positive, price : positif/neutre/negatif, risks : positif/neutre/negatif
Triggered rules
| Rule | Weight |
|---|---|
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
| moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger | +0.5 |
Thesis
The fundamental reading shows margin expansion and cash conversion making progress toward the 2027 target, for an estimated PER close to 20, below the historical range. The technical flow is healthy, carried by the session and supported by a repurchase of 4,5 % of the capital. The risk layer remains loaded with legacies, with the Muddy Waters case, adjusted metrics and family governance, while the BCE meeting of 10/09 is the next market event.
Bull case
The bullish argument rests on a large-scale repurchase of 4,5 % of the capital committed since 24/04/2026, complemented by institutional purchases during the session, with flows up 79,6 % over two years. Profitability is improving, with adjusted earnings per share up 29 % and cash conversion of 47 %. The valuation multiple sits at the floor of its historical range.
Bear case
Earnings growth rests on the margin, on the share repurchase and on finance costs, while reported revenue grows by only 2,5 %. The memory of the Muddy Waters case of June 2024 maintains a structural distrust premium on accounting quality, a legacy that adjusted metrics and family governance continue to fuel.
Scenarios
The bullish scenario, with a probability of around 25 %, assumes a rise of the PER toward around 24, underpinned by 2027 earnings per share estimated at around 3,6. The central scenario, around 50 %, rests on the persistence of a PER close to 20 and on medium-term growth. The bearish scenario, around 25 %, corresponds to a marked pullback in the share price. In this framework, invalidation of the thesis would in practice occur well before the maximum magnitude of the envisioned pullback.
Risks
The main risks relate to accounting quality and governance: memory of the Muddy Waters case of June 2024, use of adjusted metrics and family control of the company. Reported growth remains modest, at 2,5 %, and earnings growth depends more on the margin, the share repurchase and finance costs than on revenue. The BCE meeting of 10/09 is a market event to watch. A lasting break of the reference technical levels would mark invalidation of the thesis.
Upcoming catalysts
| Date | Description |
|---|---|
| Q3 2026 results and confirmation of 2027 trajectory | |
| Investor day: CDMO genomic pipeline update |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (3/3) | Unchanged. No new dated fact subsequent to the verdict of 31/08/2026: the share price of 72,78 EUR holds steady, the repurchase of 24/04 and the dividend of 28/04 precede the last verdict, and the decline in the deterministic score from +5,00 to +3,50 results from a recalculation of rules and not a market event. The weak signal is renewed. This content is informative and does not constitute investment advice. | |
| weak (single draw, outside the three-draw protocol) | unchanged | |
| weak (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
Why is the signal described as weak?
The signal is weak despite a vote of 3/3 and a score of 3,5. The fundamental layer is improving, with margin expansion, cash conversion making progress toward the 2027 target and an estimated PER close to 20, below the historical range. But the risk layer remains loaded, with Muddy Waters, adjusted metrics and family governance, and the BCE meeting of 10/09 comes up in the near term.
Why does the share repurchase support the stock?
The company has been repurchasing 4,5 % of its capital since 24/04/2026, a large-scale commitment. Institutional purchases during the session complement this support, with flows up 79,6 % over two years. This repurchase is among the drivers of the growth in adjusted earnings per share, up 29 %, alongside margin expansion and the effect of finance costs.
What doubts weigh on accounting quality?
The Muddy Waters report published in June 2024 left a lasting mark. Investors retain a structural distrust premium on the group's accounting quality, fed by the use of adjusted metrics and by family governance. This distrust is reinforced by reported revenue growth limited to 2,5 %, while earnings progress mainly through the margin, the repurchase and finance costs.
What scenarios are considered?
Three scenarios frame the analysis. A bullish scenario, with a probability of around 25 %, assumes a rise of the multiple toward around 24 times 2027 earnings estimated at around 3,6 per share. The central scenario, around 50 %, counts on the persistence of a PER close to 20. The bearish scenario, around 25 %, describes a marked pullback, with invalidation of the thesis occurring well before the maximum magnitude of the envisioned pullback.
Have any new facts emerged since the last verdict?
No. No new dated fact has occurred after the verdict of 31/08/2026. The share price of 72,78 EUR holds steady, the repurchase of 24/04 and the dividend of 28/04 precede this verdict, and the deterministic score moved from +5,00 to +3,50 following a recalculation of rules, and not a market event. The weak signal is renewed.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital (AMF · Informations réglementées continues)
- — Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version) (AMF · Informations réglementées continues)
- — Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version) (AMF · Informations réglementées continues)
- — Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version) (AMF · Informations réglementées continues)
- — Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version) (AMF · Informations réglementées continues)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 2, 2026; this page was completed on September 4, 2026 at 00:02 (UTC).
- Interests: no position in the stock analysed (ERF.PA) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: Equifax Inc (EFX)
- All analysed stocks
- Public methodology